'But Eli Lilly’s preliminary donanemab results also reveal a sobering risk of brain swelling and hemorrhaging, side effects that the company disclosed may be linked to two—perhaps three—deaths in the clinical trial and that echo hazards seen with lecanemab, which is being marketed by Eisai and Biogen.'

https://www.science.org/content/article/it-s-not-miracle-drug-eli-lilly-antibody-slows-alzheimer-s-disease-safety-issues-linger?utm_source=sfmc&utm_medium=email&utm_campaign=DailyLatestNews&utm_content=alert&et_rid=33948539&et_cid=4717688